The biologic was associated with reduced infection risk when compared with anti-TNF agents or tofacitinib in a real-world analysis of nearly 90 million patients.
A new network meta-analysis suggests that the selective JAK inhibitor upadacitinib ranks first with respect to clinical remission and response among UC treatments, researchers say.